Approval · Notice of Compliance 15092 · 2014
CIMZIA: Notice of Compliance 15092
Issued January 2, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15092
- Date
- January 2, 2014
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: cimzia alone or in combination with methotrexate (mtx) is indicated for reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with mopderately to severely active psoriatic arthritis (psa) who have failed one or more disease-modifying anti-rheumatic drugs (dmards)
- Therapeutic class
- Biological response modifier
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CIMZIA | Not yet assigned | — |
Medicinal ingredients
- CERTOLIZUMAB PEGOL 200 MG per ML